KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$281.2 million.

  • Supernus Pharmaceuticals' Enterprise Value rose 3026.96% to -$281.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$281.2 million, marking a year-over-year increase of 3026.96%. This contributed to the annual value of -$453.6 million for FY2024, which is 7797.5% down from last year.
  • Supernus Pharmaceuticals' Enterprise Value amounted to -$281.2 million in Q3 2025, which was up 3026.96% from -$522.6 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Enterprise Value peaked at -$151.7 million during Q2 2023, and registered a low of -$522.6 million during Q2 2025.
  • For the 5-year period, Supernus Pharmaceuticals' Enterprise Value averaged around -$353.4 million, with its median value being -$360.8 million (2022).
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 5796.52% in 2023, then plummeted by 12893.06% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Enterprise Value stood at -$339.7 million in 2021, then crashed by 35.81% to -$461.3 million in 2022, then surged by 44.75% to -$254.9 million in 2023, then tumbled by 77.97% to -$453.6 million in 2024, then skyrocketed by 38.02% to -$281.2 million in 2025.
  • Its last three reported values are -$281.2 million in Q3 2025, -$522.6 million for Q2 2025, and -$463.6 million during Q1 2025.